The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed at $30.81 in the last session, down -5.49% from day before closing price of $32.6. In other words, the price has decreased by -$5.49 from its previous closing price. On the day, 2.18 million shares were traded. OLMA stock price reached its highest trading level at $33.105 during the session, while it also had its lowest trading level at $30.47.
Ratios:
We take a closer look at OLMA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.03 and its Current Ratio is at 8.03. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Guggenheim on October 08, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On August 12, 2025, Citigroup reiterated its Buy rating and also lowered its target price recommendation from $20 to $21.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $24.Goldman initiated its Buy rating on April 02, 2024, with a $24 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 18 ’25 when Harmon Cyrus sold 10,000 shares for $8.33 per share. The transaction valued at 83,300 led to the insider holds 744,140 shares of the business.
Harmon Cyrus sold 10,000 shares of OLMA for $80,400 on Sep 16 ’25. The Director now owns 754,140 shares after completing the transaction at $8.04 per share. On Sep 18 ’25, another insider, Harmon Cyrus, who serves as the Director of the company, sold 3,086 shares for $8.32 each. As a result, the insider received 25,676 and left with 117,028 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 2469726976 and an Enterprise Value of 1790930176.
Stock Price History:
The Beta on a monthly basis for OLMA is 1.87, which has changed by 4.344262 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $36.26, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is 79.10%, while the 200-Day Moving Average is calculated to be 270.47%.
Shares Statistics:
According to the various share statistics, OLMA traded on average about 3.66M shares per day over the past 3-months and 3435520 shares per day over the past 10 days. A total of 68.65M shares are outstanding, with a floating share count of 65.65M. Insiders hold about 16.54% of the company’s shares, while institutions hold 75.10% stake in the company. Shares short for OLMA as of 1764288000 were 10810748 with a Short Ratio of 2.95, compared to 1761868800 on 8366665. Therefore, it implies a Short% of Shares Outstanding of 10810748 and a Short% of Float of 14.63.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 7.0 analysts currently analyzing and rating the stock of Olema Pharmaceuticals Inc (OLMA).The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.51 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$1.83 and -$2.22 for the fiscal current year, implying an average EPS of -$1.93. EPS for the following year is -$2.33, with 6.0 analysts recommending between -$1.86 and -$2.66.
